1026.2500 -7.55 (-0.73%)
NSE Sep 18, 2025 12:51 PM
Volume: 559.4K
 

1026.25
-0.73%
IDBI Capital
Cadila results were below our estimates, sales were at Rs21.4bn (est. Rs25.4bn) taking into account higher than expected de-stocking on account of GST implementation. Management guided the EBITDA margins at 18% for Q1FY18 post adjustment of GST impact at the similar levels as of Q4FY17. PAT was at Rs1.4bn 66% down YoY and 64.7% down QoQ. While the Gross margins have fallen from 65.1% in Q1FY17 to 61.2% in Q1FY18, which were lower than our estimates as we had accounted for some gLialda inventory push during the quarter. However, with the management guiding the...
Zydus Lifesciences L.. has an average target of 1045.33 from 6 brokers.
More from Zydus Lifesciences Ltd.
Recommended